BACKGROUND Acyclovir (ACV), a highly specific anti-herpetic drug, acts as a DNA chain terminator for several human herpesviruses (HHVs), including HHV-2 (HSV-2), a common human immunodeficiency virus (HIV)-1 co-pathogen. Several trials demonstrated that HSV-2 suppressive therapy using ACV or its prodrug valacyclovir (valACV) reduced plasma HIV-1 viral load (VL) in HIV-1/HSV-2 coinfected persons...

BACKGROUND Despite the proven efficacy of acyclovir (ACV) therapy, herpes simplex encephalitis (HSE) continues to cause substantial morbidity and mortality. Among patients with HSE treated with ACV, the mortality rate is approximately 14%-19%. Among survivors, 45%-60% have neuropsychological sequelae at 1 year. Thus, improving therapeutic approaches to HSE remains a high priority. METHODS Fol...

BACKGROUND Herpes simplex keratitis (HSK) caused by herpes simplex virus 1 (HSV-1), which has high recurrent rate and incidence of severe vision loss, is the leading cause of infectious blindness in the world. The aim was to explore the clinical efficacy of oral ganciclovir (GCV) in the prevention of recurrent HSK. METHODS A multicenter, prospective, randomized, single-blind, and controlled c...

the purpose of the research was to formulate microspheres of acyclovir (acv) using mucoadhesive polymers, sodium alginate and chitosan. calcium chloride was used as the ionotropic gelling agent. sodium alginate was crosslinked by calcium chloride leading to a slower release of the drug. chitosan which is a cationic polymer interacted with sodium alginate, an anionic polymer, to form an interpol...

Background: Acyclovir (ACV) a 21-deoxy guanosine analogue effective against Herpes Simplex Virus (both type 1 and 2) other viral diseases, mainly acts by inhibiting the DNA polymerase. The limited oral bioavailability of ACV (5-10%) requires higher dosage (400-800 mg), results in neurotoxicity renal failure. Topically, lower efficacy is attributed to inadequate drug permeation across stratum co...

The purpose of the research was to formulate microspheres of acyclovir (ACV) using mucoadhesive polymers, sodium alginate and chitosan. Calcium chloride was used as the ionotropic gelling agent. Sodium alginate was crosslinked by calcium chloride leading to a slower release of the drug. Chitosan which is a cationic polymer interacted with sodium alginate, an anionic polymer, to form an interpol...

Chain-terminating nucleoside analogs (CTNAs) that cause stalling or premature termination of DNA replication forks are widely used as anticancer and antiviral drugs. However, it is not well understood how cells repair the DNA damage induced by these drugs. Here, we reveal the importance of tyrosyl-DNA phosphodiesterase 1 (TDP1) in the repair of nuclear and mitochondrial DNA damage induced by CT...

Although a number of antiviral drugs inhibit replication of Epstein-Barr virus (EBV) in cell culture, and acyclovir (ACV) suppresses replication in vivo, currently available drugs have not proven effective for treatment of EBV-associated diseases other than oral hairy leukoplakia. Benzimidazole riboside compounds represent a new class of antiviral compounds that are potent inhibitors of human c...

Herpes simplex virus type 1 (HSV-1) causes a lifelong latent infection with an estimated global prevalence of 66%. Primary and recurrent HSV infections are characterized by tingling sensation, followed eruption vesicles, which can cause painful erosions. Commonly used antiviral drugs against nucleoside analogues including acyclovir (ACV), famciclovir, valacyclovir. Although these reduce morbidi...